心房颤动(房颤)是临床最常见的心律失常,增加脑卒中的发病率和死亡率.抗凝治疗是预防房颤合并脑卒中的有效手段.目前能够长期服用的口服抗凝药物只有华法林,但华法林存在个体差异、复杂的药物和药物及药物和食物之间的相互作用,需要定期抗凝监测和频繁调整剂量,具有局限性.研发新型口服抗凝药成为新的热点,活化凝血因子X抑制剂和凝血酶抑制剂在房颤抗凝领域的研究进展迅速,已经取得了明确的循证医学证据.现将这一领域的研究进展做一综述.%Atrial fibrillation is the most common arrhythmia and increases the morbidity and mortality from stroke. Anticoagulant therapy is an effective measure to prevent stroke. Now the available drug for long-term use is limited to warfarin. But warfarin has the limitations of great individual differences and complex drug-drug and drug-food interaction which need regular monitoring and dose adjustment. Developments of new oral anticoagulants have become the new hot spot. The novel oral factors Xa and thrombin inhibitors have get rapid progress and obtained clear evidence-based data. Now progress in this area is reviewed.
展开▼
